Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Feb 2010

Wells Samuel A, Gosnell Jessica E, Gagel Robert F, Moley Jeffrey, Pfister David, Sosa Julie A, Skinner Michael, Krebs Annetta, Vasselli James, Schlumberger Martin

Abstract excerpt

PURPOSE There is no effective therapy for patients with distant metastasis of medullary thyroid carcinoma (MTC). Activating mutations in the RET proto-oncogene cause hereditary MTC, which provides a strong therapeutic rationale for targeting RET kinase activity. This open-label, phase II study assessed the efficacy of vandetanib, a selective oral inhibitor of RET, vascular endothelial growth factor receptor, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Calcitonin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoembryonic Antigen

Share to Carcinoma, Medullary

Share to Drug Administration Schedule

Share to Piperidines

Share to Proto-Oncogene Mas

Share to Proto-Oncogene Proteins c-ret

Source

Open in PubMed Open full text

Identifiers

PMID: 20065189
DOI: 10.1200/JCO.2009.23.6604
PMCID: PMC2834392

Genes

RET

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.PMID 20065189Read ↗

Systemic treatment and management approaches for medullary thyroid cancer.Semantic proximity Read ↗

Management of hereditary medullary thyroid carcinoma.Semantic proximity Read ↗

Molecular genetics, therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectivesSemantic proximity Read ↗

Update on the Treatment of Medullary Thyroid Carcinoma in Patients with Multiple Endocrine Neoplasia Type 2.Semantic proximity Read ↗

Prognostic markers and response to vandetanib therapy in sporadic medullary thyroid cancer patients.Semantic proximity Read ↗

MANAGEMENT OF ENDOCRINE DISEASE: Medullary thyroid cancer: from molecular biology and therapeutic pitfalls to future targeted treatment perspectivesSemantic proximity Read ↗

Recent advances in the molecular pathogenesis and targeted therapies of medullary thyroid carcinoma.Semantic proximity Read ↗

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.Semantic proximity Read ↗

Medullary Thyroid Cancer: Molecular Biology and Novel Molecular TherapiesSemantic proximity Read ↗

Medullary Thyroid Cancer: Clinical Characteristics and New Insights into Therapeutic Strategies Targeting Tyrosine Kinases.Semantic proximity Read ↗

Targeting RET Receptor Tyrosine Kinase Activation in CancerSemantic proximity Read ↗

Libretto-531: A Phase III Study of Selpercatinib in Multikinase Inhibitor-Naïve RET -Mutant Medullary Thyroid CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.